Protara Therapeutics
TARA
29 hedge funds and large institutions have $12.3M invested in Protara Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3.24% less ownership
Funds ownership: 48.66% → 45.42% (-3.2%)
27% less capital invested
Capital invested by funds: $16.9M → $12.3M (-$4.62M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$73.4K |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$34.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.86K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.57K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$5.7K |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$908K |
| 2 |
Morgan Stanley
New York
|
-$183K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$107K |
| 4 |
O
OrbiMed
New York
|
-$62.3K |
| 5 |
Millennium Management
New York
|
-$5.27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $1.35K | +$9 | +3 | +0.5% |
|
27
Osaic Holdings
Scottsdale,
Arizona
| $239 | – | – | – |
|
28
Fidelity Investments
Boston,
Massachusetts
| $23 | +$27 | +9 | New |
|
|
PA
29
Perceptive Advisors
New York
| – | -$908K | -290,051 | Closed |
|
|
30
Morgan Stanley
New York
| – | -$183K | -58,364 | Closed |
|
31
UBS Group
Zurich,
Switzerland
| – | -$3.04K | -971 | Closed |
|
32
Simplex Trading
Chicago,
Illinois
| – | +$579 | +195 | New |
|
TARA Hedge Fund Activity: Q2 2023 in Review
29 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2023, worth a combined $12.3M — down 27% from $16.9M a quarter earlier.
Fund positioning in TARA was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $73.4K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $908K sold.
- 29 institutional investors held Protara Therapeutics (TARA) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $12.3M of Protara Therapeutics stock for Q2 2023, down 27% quarter-over-quarter.
- 3 funds opened new Protara Therapeutics positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Protara Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $73.4K added.
- The largest Protara Therapeutics seller in Q2 2023 was Perceptive Advisors, an estimated $908K sold.
Based on aggregated 13F filings for Q2 2023.